A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists a Phase 2 study of elamipretide topical ophthalmic solution for Leber's hereditary optic neuropathy as completed. The randomized, double-masked, vehicle-controlled study was designed to evaluate safety, tolerability, and efficacy in approximately 12 participants; the excerpt provides no results.
- 01The prospective study was conducted at a single center.
- 02The protocol specified 52 weeks of treatment, followed by an optional open-label extension of up to 48 additional weeks.
- 03Completed status does not establish safety or efficacy; no outcome data are included.
Why it matters Editorial
The listing documents clinical investigation of Elamipretide for Leber's hereditary optic neuropathy, but the excerpt does not support conclusions about its benefits or risks.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide